Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I2YV
|
|||
| Former ID |
DIB013351
|
|||
| Drug Name |
BIBB-515
|
|||
| Synonyms |
BIBB 515; BIBB-515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Terminated | [1] | |
| Company |
Dr Karl Thomae GmbH
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21ClN2O2
|
|||
| Canonical SMILES |
C1CN(CCC1=CC2=CC=C(C=C2)C3=NCCO3)C(=O)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C22H21ClN2O2/c23-20-7-5-19(6-8-20)22(26)25-12-9-17(10-13-25)15-16-1-3-18(4-2-16)21-24-11-14-27-21/h1-8,15H,9-14H2
|
|||
| InChIKey |
JQNWPWUJMRAASQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 156635-05-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lanosterol synthase (LSS) | Target Info | Modulator | [1], [2] |
| BioCyc | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | |||
| Cholesterol biosynthesis III (via desmosterol) | ||||
| Cholesterol biosynthesis I | ||||
| Superpathway of cholesterol biosynthesis | ||||
| Lanosterol biosynthesis | ||||
| KEGG Pathway | Steroid biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| Cholesterol biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75. | |||
| REF 2 | Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.